Drugs / CAR2 Anti-CEA CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03818165 | Jul 2019 → Jan 2020 | carcinoma | Sorrento Therapeutics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR2 Anti-CEA CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03818165 ↗ |
| Modality | Cell therapy | “CAR2 Anti-CEA CAR-T cells” NCT03818165 ↗ |